- Announced June 25, 2026 by Merck KGaA and Bio-Techne. The merger agreement is dated June 25, 2026. The joint press release says the deal was approved by Bio-Techne’s board of directors and by the relevant corporate bodies of Merck KGaA.
- This page is about Merck KGaA, a German company, not Merck & Co. Bio-Techne’s employee Q&A of June 25, 2026 says Merck KGaA is a different company than Merck & Co.
- Consideration is all cash, $73 for each share of Bio-Techne common stock, without interest and less any required tax withholding (Section 2.01(a)(i) of the merger agreement). The joint press release says the price represents an enterprise value of approximately $11.3 billion.
- Expected close, as the companies stated at announcement, by late 2026 or early 2027, subject to customary closing conditions, including required regulatory approvals and approval by Bio-Techne’s shareholders. Bio-Techne repeated that timing in its quarterly report dated November 6, 2026, and its employee FAQ of September 9, 2026 said a specific closing date had not been scheduled. In its third quarter results release of November 12, 2026, Merck KGaA said its guidance reflected the acquisition of Bio-Techne for the month of December 2026, called this an assumption, and said the actual closing date may differ.
- The closing conditions include approval by Bio-Techne’s shareholders, the end of the waiting period under the Hart-Scott-Rodino Act, and approvals under antitrust and investment screening laws in the jurisdictions listed in a disclosure letter that isn’t in the filed agreement (Section 6.01(a) and (b)).
- Bio-Techne said its shareholders approved the merger agreement at a special meeting on September 23, 2026, and that the Hart-Scott-Rodino waiting period expired on September 18, 2026. It told employees on August 25, 2026 that the deal received unconditional approval from the German Federal Cartel Office on August 17, 2026, and on September 9, 2026 that approvals in other countries were in process. Its September 23, 2026 release said closing was subject to customary conditions, including receipt of remaining required regulatory approvals.
- Either Merck KGaA or Bio-Techne can generally end the agreement if the merger has not closed by March 25, 2027. If the conditions still open on that date all relate to antitrust or investment screening law, and every other condition has been met, waived or can be met, the date extends automatically to June 25, 2027. If that is still true on June 25, 2027, it extends again to September 25, 2027, a Saturday. The parties can agree in writing to extend it further (Section 7.01(b)(i)).
- Closing takes place on the fifth business day after the last closing condition is met or waived, unless the parties agree in writing on another date (Section 1.02). When the merger takes effect, Bio-Techne survives as a wholly owned subsidiary of Merck KGaA, and Bio-Techne’s proxy statement says its shares will no longer be listed or traded on Nasdaq.
- Vested options with an exercise price below $73 are cancelled at close for cash equal to $73 minus the exercise price for each share, less tax withholding, due no later than the first administratively practicable payroll period after close (Section 2.03(a)(i) and (g)). Options with an exercise price of $73 or more are cancelled with no payment, whether or not vested (Section 2.03(a)).
- Unvested options with an exercise price below $73 become fixed cash awards for the same amount, $73 minus the exercise price for each share. Each piece vests on the option’s schedule, including any acceleration terms, and is paid within 15 business days after it vests. Performance conditions on an option count at target (Section 2.03(a)(ii)).
- RSUs that vest with time alone, whether vested or unvested at close, become fixed cash awards of $73 for each RSU, rounded to the nearest cent, under generally the same terms, including service based and accelerated vesting terms (Section 2.03(b)). Bio-Techne told employees on July 9, 2026 that these cash awards would continue to vest and be paid, less tax withholding, on the same time based schedule. Restricted stock becomes a similar fixed cash award, with any performance conditions counted at target (Section 2.03(d)).
- PSUs become the same kind of fixed cash award, $73 for each unit, on generally the same terms, including service based and accelerated vesting terms. For any performance period not completed at close, the number of units counts at maximum performance, and the award then vests on service alone (Section 2.03(c)). Any award payment under Section 2.03 that is deferred compensation under Section 409A is instead paid at the earliest time its terms allow without a Section 409A tax or penalty (Section 2.03(g)).
- Bio-Techne told employees on July 9, 2026 that the ESPP cycle then running would end as scheduled in August 2026, with contributions used to buy shares at its end, and on September 9, 2026 that the cycle had ended as scheduled and no new cycle would begin. Under the merger agreement, no new phase of the plan starts and the plan ends no later than just before close (Section 2.03(f)). ESPP shares you still hold at close become $73 in cash, like any other Bio-Techne share (Section 2.01(a)(i)). Bio-Techne’s annual report says its 2014 Employee Stock Purchase Plan is designed to comply with IRS provisions governing employee stock purchase plans.
- In the merger agreement, Merck KGaA agreed with Bio-Techne that for 12 months after the closing date, or less if your employment ends sooner, it would provide each Bio-Techne employee base pay no lower than before close. Total target cash compensation, which the agreement says is made up of base pay, target short term cash incentive opportunity and target equity or long term incentive opportunity, is to be no less favorable in the aggregate, and so are employee benefits, with some exclusions. Severance is to be no less favorable than what is set out in a disclosure letter that isn’t in the filed agreement (Section 5.10(a)). The agreement says Merck KGaA does not have to keep anyone employed for any specific period, and that no employee is a third party beneficiary of the agreement, which generally means employees can’t enforce these terms themselves (Section 5.10(a) and (j)).
- On the first regularly scheduled payroll date after the closing date, each person employed by Bio-Techne or its subsidiaries just before close is to be paid a pro rata annual bonus for the fiscal year of close. It is the greater of target and the bonus earned on actual performance through close, prorated for the part of that fiscal year before close. Any unpaid bonus for a fiscal year already completed is paid then too, at no less than actual performance (Section 5.10(d)). Bio-Techne’s fiscal year 2027 runs July 1, 2026 through June 30, 2027, and its September 9, 2026 employee FAQ said that if the deal closed before that year ended, bonuses would be prorated through close and paid following close.
- Bio-Techne’s proxy statement says its compensation committee approved cash retention bonus agreements with its executive officers, senior vice presidents and vice presidents, and a retention bonus pool of up to $22,000,000. The pool is for critical talent or select employees below vice president level with a heavier workload related to the closing, and for payments to disqualified individuals under Section 280G, other than the named executive officers.
- Bio-Techne told employees on September 9, 2026 that no decisions had been made regarding future workforce impacts, and that after close their years of service with Bio-Techne would generally be recognized under applicable Merck KGaA benefit plans, which may include eligibility, vesting, paid time off and severance. The FAQ says it is not legally binding, and that the merger agreement and plan documents control if they conflict.
Sources. Merck KGaA and Bio-Techne joint press release, June 25, 2026, Bio-Techne’s Form 8-K with the merger agreement dated June 25, 2026 as Exhibit 2.1, Bio-Techne’s definitive proxy statement, dated August 20, 2026, Bio-Techne’s employee communications of June 25, 2026, July 9, 2026, August 25, 2026 and September 9, 2026, filed with the SEC, Bio-Techne’s release of September 23, 2026 on the shareholder vote, Bio-Techne’s Form 10-Q for the quarter ended September 30, 2026, Bio-Techne’s Form 10-K for the fiscal year ended June 30, 2026, and Merck KGaA’s third quarter 2026 results release, November 12, 2026. BFA Wealth Management isn’t affiliated with Merck KGaA, Merck & Co. or Bio-Techne. The terms and dates above come from the announcement and filings named here, as of the date the facts were checked. They can change before close, so confirm the treatment of your own awards with HR before you act.
